ArticlePloS one2025
GDNF receptor GFRα1 is necessary for the maintenance of dopaminergic neurons in the adult substantia nigra.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Converging neurotrophic-immune signaling in autism spectrum disorder: integrative roles of klotho, GDNF/GFRA-1, IGF-1 and GLP-1 pathways.Metabolic brain disease · 2026Review
- Phosphodiesterase Inhibition Increases Striatal GDNF and Protects Against Preclinical Parkinsonism.Journal of neurochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GFRα1 and Ret are the two necessary components of the receptor for GDNF, a neurotrophic factor discovered in the early 1990's for its ability to support the survival of midbrain dopaminergic neurons, including those in the substantia nigra (SN) that project to the dorsal striatum (dSTR) and degenerate in Parkinson's Disease. Several GDNF clinical trials have been conducted to date with mixed results. Despite the physiological and clinical importance of this signaling system, whether any of its components are required for the maintenance of adult SN neurons has not yet been elucidated. In this study, we first analyzed postnatal expression patterns of Gfrα1 and Ret in the SN and established that mRNA levels peak at mouse postnatal day 15 (P15), stabilizing after P30. Using Tamoxifen-induced deletion of Gfrα1 at 3 months of age, we found that GFRα1 is required for the maintenance of a subset of adult SN dopaminergic neurons. FluoroGold tracing of SN axons from the dSTR in mutant mice revealed that ablation of GFRα1 preferentially affects the subset of GFRα1-expressing neurons that project to the STR. In addition to the well-known neuroprotective functions of GDNF/GFRα1/RET signaling, our results establish a physiological requirement of the GFRα1 component of this neurotrophic system for the continuous maintenance of SN dopaminergic neurons in the adult brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.